Skip to main content
Top
Published in: Clinical Rheumatology 11/2007

01-11-2007 | Case Report

Microscopic polyangiitis and myasthenia gravis: the battle of Occam and Hickam

Authors: Michael V. Holmes, Debajit Sen

Published in: Clinical Rheumatology | Issue 11/2007

Login to get access

Abstract

Microscopic polyangiitis (MPA) is a pauci-immune, necrotising, small-vessel vasculitis with an incidence of 3.6 per million population that typically presents in adulthood. Myasthenia gravis (MG), the most common disorder of the neuromuscular junction is rare, with an incidence of four per million population. We present the case of an adolescent girl previously diagnosed with MPA at age 7 years who presented with breathlessness and respiratory failure aged 15 years. The respiratory symptoms were due to thymoma-MG, which was successfully treated with cholinesterase inhibitors and thymectomy. This case report illustrates that the well-established doctrines of Occam’s razor and of ‘common conditions occurring commonly’ are not universally applicable, and that in the adolescent age group, one should still consider Hickam’s dictum.
Literature
1.
go back to reference Guillevin L, Durand-Gasselin B, Cevallos R et al (1999) Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 42(3):421–430PubMedCrossRef Guillevin L, Durand-Gasselin B, Cevallos R et al (1999) Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 42(3):421–430PubMedCrossRef
2.
go back to reference Clinical features of primary ANCA-associated vasculitis. In: Isenberg D, Maddison P, Woo P et al (eds) (2004) Oxford textbook of rheumatology, 3rd edn. Oxford University Press, Oxford, pp 943–957 Clinical features of primary ANCA-associated vasculitis. In: Isenberg D, Maddison P, Woo P et al (eds) (2004) Oxford textbook of rheumatology, 3rd edn. Oxford University Press, Oxford, pp 943–957
3.
go back to reference Davenport A, Lock RJ, Wallington TB, Feest TG (1994) Clinical significance of anti-neutrophil cytoplasm antibodies detected by a standardized indirect immunofluorescence assay. Q J Med 87(5):291–299, (May)PubMed Davenport A, Lock RJ, Wallington TB, Feest TG (1994) Clinical significance of anti-neutrophil cytoplasm antibodies detected by a standardized indirect immunofluorescence assay. Q J Med 87(5):291–299, (May)PubMed
4.
go back to reference Millichap JG, Dodge PR (1960) Diagnosis and treatment of myasthenia gravis in infancy, childhood, and adolescence: a study of 51 patients. Neurology 10:1007–1014PubMed Millichap JG, Dodge PR (1960) Diagnosis and treatment of myasthenia gravis in infancy, childhood, and adolescence: a study of 51 patients. Neurology 10:1007–1014PubMed
5.
go back to reference Qureshi A, Choundry M, Mohammad Y et al (2004) Respiratory failure as a first presentation of myasthenia gravis. Med Sci Monit 10(12):CR684–CR689PubMed Qureshi A, Choundry M, Mohammad Y et al (2004) Respiratory failure as a first presentation of myasthenia gravis. Med Sci Monit 10(12):CR684–CR689PubMed
6.
go back to reference Berrouschot J, Baumann I, Kalischewski P et al (1997) Therapy of myasthenic crisis. Crit Care Med 25(7):1228–1235PubMedCrossRef Berrouschot J, Baumann I, Kalischewski P et al (1997) Therapy of myasthenic crisis. Crit Care Med 25(7):1228–1235PubMedCrossRef
7.
go back to reference Castleman B (1966) The pathology of the thymus gland in myasthenia gravis. Ann N Y Acad Sci 135(1):496–505PubMedCrossRef Castleman B (1966) The pathology of the thymus gland in myasthenia gravis. Ann N Y Acad Sci 135(1):496–505PubMedCrossRef
8.
go back to reference Romi F, Gilhus NE, Varhaug JE et al (2003) Disease severity and outcome in thymoma myasthenia gravis: a long-term observation study. Eur J Neurol 10(6):701–706PubMedCrossRef Romi F, Gilhus NE, Varhaug JE et al (2003) Disease severity and outcome in thymoma myasthenia gravis: a long-term observation study. Eur J Neurol 10(6):701–706PubMedCrossRef
9.
go back to reference Muller-Hermelink HK, Marx A, Geuder K et al (1993) The pathological basis of thymoma-associated myasthenia gravis. Ann N Y Acad Sci 681:56–65PubMedCrossRef Muller-Hermelink HK, Marx A, Geuder K et al (1993) The pathological basis of thymoma-associated myasthenia gravis. Ann N Y Acad Sci 681:56–65PubMedCrossRef
10.
go back to reference Romi F, Bo L, Skeie GO et al (2002) Titin and ryanodine receptor epitopes are expressed in cortical thymoma along with costimulatory molecules. J Neuroimmunol 128(1–2):82–89PubMedCrossRef Romi F, Bo L, Skeie GO et al (2002) Titin and ryanodine receptor epitopes are expressed in cortical thymoma along with costimulatory molecules. J Neuroimmunol 128(1–2):82–89PubMedCrossRef
11.
go back to reference Perlo VP, Poskanzer DC, Schwab RS (1966) Myasthenia gravis: evaluation of treatment in 1,355 patients. Neurology 16(5):431–439PubMed Perlo VP, Poskanzer DC, Schwab RS (1966) Myasthenia gravis: evaluation of treatment in 1,355 patients. Neurology 16(5):431–439PubMed
12.
go back to reference Roses AD, Olanow CW, McAdams MW et al (1981) No direct correlation between serum antiacetylcholine receptor antibody levels and clinical state of individual patients with myasthenia gravis. Neurology 31(2):220–224PubMed Roses AD, Olanow CW, McAdams MW et al (1981) No direct correlation between serum antiacetylcholine receptor antibody levels and clinical state of individual patients with myasthenia gravis. Neurology 31(2):220–224PubMed
13.
go back to reference Warrell DA (2004) Disorders of the neuromuscular junction. In: Warrell DA, Cox TM, Firth JD, Benz EJ (eds) Oxford textbook of medicine, 4th edn. Oxford University Press, Oxford, (Section 24.42) Warrell DA (2004) Disorders of the neuromuscular junction. In: Warrell DA, Cox TM, Firth JD, Benz EJ (eds) Oxford textbook of medicine, 4th edn. Oxford University Press, Oxford, (Section 24.42)
14.
go back to reference Swaak T, Smeenk R (1985) Detection of anti-dsDNA as a diagnostic tool: a prospective study in 441 non-systemic lupus erythematosus patients with anti-dsDNA antibody (anti-dsDNA). Ann Rheum Dis 44(4):245–251, (Apr)PubMedCrossRef Swaak T, Smeenk R (1985) Detection of anti-dsDNA as a diagnostic tool: a prospective study in 441 non-systemic lupus erythematosus patients with anti-dsDNA antibody (anti-dsDNA). Ann Rheum Dis 44(4):245–251, (Apr)PubMedCrossRef
15.
go back to reference ter Borg EJ, Horst G, Hummel E et al (1991) Rises in anti-double stranded DNA antibody levels prior to exacerbations of systemic lupus erythematosus are not merely due to polyclonal B cell activation. Clin Immunol Immunopathol 59(1):117–128, AprPubMedCrossRef ter Borg EJ, Horst G, Hummel E et al (1991) Rises in anti-double stranded DNA antibody levels prior to exacerbations of systemic lupus erythematosus are not merely due to polyclonal B cell activation. Clin Immunol Immunopathol 59(1):117–128, AprPubMedCrossRef
Metadata
Title
Microscopic polyangiitis and myasthenia gravis: the battle of Occam and Hickam
Authors
Michael V. Holmes
Debajit Sen
Publication date
01-11-2007
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 11/2007
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-007-0599-9

Other articles of this Issue 11/2007

Clinical Rheumatology 11/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine